Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Piper Sandler dropped their Q1 2020 earnings per share estimates for shares of Illumina in a research report issued to clients and investors on Wednesday, January 29th. Piper Sandler analyst W. Quirk now anticipates that the life sciences company will earn $1.25 per share for the quarter, down from their prior estimate of $1.52. Piper Sandler currently has a “Overweight” rating and a $370.00 target price on the stock. Piper Sandler also issued estimates for Illumina’s Q3 2020 earnings at $1.88 EPS, Q4 2020 earnings at $2.03 EPS, Q1 2021 earnings at $1.83 EPS, Q3 2021 earnings at $2.03 EPS and Q4 2021 earnings at $2.22 EPS.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.12. Illumina had a net margin of 28.27% and a return on equity of 22.78%. The firm had revenue of $953.00 million for the quarter, compared to analysts’ expectations of $950.16 million. During the same period last year, the firm earned $1.32 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis.
ILMN has been the topic of a number of other reports. BidaskClub cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Friday. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $341.00 price objective on the stock. in a research note on Monday, January 20th. Wells Fargo & Co reduced their price objective on shares of Illumina from $300.00 to $290.00 and set an “underweight” rating on the stock in a research note on Thursday. Wolfe Research set a $380.00 price objective on shares of Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Stifel Nicolaus assumed coverage on shares of Illumina in a research note on Thursday, November 14th. They issued a “buy” rating and a $345.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $335.13.
Shares of ILMN stock opened at $290.07 on Monday. Illumina has a 52-week low of $263.30 and a 52-week high of $380.76. The stock has a market cap of $42.64 billion, a PE ratio of 42.97, a PEG ratio of 2.16 and a beta of 1.05. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. The firm’s 50 day moving average price is $325.45 and its two-hundred day moving average price is $306.19.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cetera Advisors LLC boosted its position in shares of Illumina by 5.4% during the third quarter. Cetera Advisors LLC now owns 679 shares of the life sciences company’s stock worth $208,000 after purchasing an additional 35 shares in the last quarter. Veritas Investment Management LLP raised its holdings in shares of Illumina by 4.8% during the fourth quarter. Veritas Investment Management LLP now owns 765 shares of the life sciences company’s stock worth $254,000 after acquiring an additional 35 shares during the period. Zeke Capital Advisors LLC raised its holdings in shares of Illumina by 2.0% during the third quarter. Zeke Capital Advisors LLC now owns 2,044 shares of the life sciences company’s stock worth $622,000 after acquiring an additional 40 shares during the period. TCI Wealth Advisors Inc. raised its holdings in shares of Illumina by 13.2% during the fourth quarter. TCI Wealth Advisors Inc. now owns 378 shares of the life sciences company’s stock worth $125,000 after acquiring an additional 44 shares during the period. Finally, Landsberg Bennett & Dubbaneh LLC raised its holdings in shares of Illumina by 2.0% during the third quarter. Landsberg Bennett & Dubbaneh LLC now owns 2,502 shares of the life sciences company’s stock worth $754,000 after acquiring an additional 48 shares during the period. 91.71% of the stock is currently owned by institutional investors.
In other news, SVP Phillip G. Febbo sold 155 shares of Illumina stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $300.00, for a total transaction of $46,500.00. Following the transaction, the senior vice president now directly owns 1,506 shares of the company’s stock, valued at $451,800. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Omead Ostadan sold 1,200 shares of Illumina stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $326.01, for a total transaction of $391,212.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,727 shares of company stock worth $1,204,837. Insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
